Guggenheim analyst Seamus Fernandez has maintained a Buy rating on Amylyx Pharmaceuticals (NASDAQ: AMLX) and raised the price target to $40. The previous target was $30. The rating and price target adjustment reflect the analyst's updated outlook on the company's stock performance.

Rating and Price Target Details

The decision to maintain the Buy rating accompanies an increase in the price objective. The following table outlines the revised figures:

The upgrade in the price target suggests increased confidence in the stock's potential upside.

Amylyx Pharmaceuticals, Inc. presented positive safety data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European Network to Cure ALS (ENCALS) Meeting 2026, held from June 24-26, 2026 in Madrid, Spain. The data showed no drug-related serious adverse events (SAEs) and no serious neurological adverse events (AEs) in Cohort 1, which evaluated the lowest dose level of 12.5 mg. These findings support the continued evaluation of AMX0114 at higher dose levels in the multiple ascending dose trial.

AMX0114 is an investigational antisense oligonucleotide (ASO) targeting calpain-2, a calcium-activated protease that drives axonal degeneration in ALS. The drug has received U.S. Food and Drug Administration (FDA) Fast Track designation. In preclinical studies, AMX0114 demonstrated potent, dose-dependent reduction in calpain-2 levels and improved neuronal survival.

The LUMINA trial (NCT06665165) is a multinational, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114. The trial is enrolling approximately 48 adult participants across four dose levels. Participants are randomized 3:1 to receive AMX0114 or placebo via intrathecal administration once every four weeks for up to four doses. Study sites are active in Canada and the United States.

Biomarker levels, including spectrin breakdown product 145 (SBDP-145), neurofilament light (NfL), and phosphorylated neurofilament heavy (pNFH), remained near baseline in Cohort 1. These markers are key indicators of neuronal damage. The stability of these markers at the lowest dose level suggests potential neuroprotective effects, which will be further investigated in future cohorts.

Cohorts 1 (12.5 mg) and 2 (25 mg) are fully enrolled, and Cohort 3 (50 mg) is currently enrolling. The company anticipates a total of four dose levels in this dose-ranging study. The presentation at the ENCALS Meeting 2026 provides early insights into the safety and biomarker effects of AMX0114, setting the stage for further clinical development.